Ofatumumab Exhibits Enhanced in Vitro and in Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4391-4397

  Barth, Matthew J ^a   Mavis, Cory ^a   Czuczman, Myron S ^b   Hernandez Ilizaliturri, Francisco J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; COMPLEMENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; COMPLEMENT ACTIVATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; IMMUNOLOGY; LYMPHOMA, MANTLE-CELL; METABOLISM; MORTALITY; PRECLINICAL STUDY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD55; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, MANTLE-CELL; MICE; MICE, SCID; RITUXIMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945351520     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0056     Document Type: Article

References (29)

1. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006;24:22-7.
2. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-8.
3. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with lowgrade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22: 4711-6.
4. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
6. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43.
7. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review andmeta-Analysis. J Natl Cancer Inst 2007;99:706-14.
8. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14:1561-70.
9. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270-81.
10. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556-63.
11. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8.
12. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010;28:3525-30.
13. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177: 362-71.
14. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800.
15. Pawluczkowycz A, Beurskens F, Beum P, Lindorfer M, van de Winkel J, Parren P, et al. Binding of submaximal C1q promotes complementdependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab(OFA) or rituximab (RTX): considerably higher levels ofCDC are induced by OFA than by RTX. J Immunol 2009;183:749-58.
16. Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181:822-32.
17. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, et al. Ofatumumab demonstrates activity against rituximab-sensitive and-resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol 2012;156:490-8.
18. Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, et al. Downregulation of deoxycytidine kinase in cytarabine-resistantmantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer 2014;13:159.
19. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008;14:1550-60.
20. Ottonello L, Morone P, Dapino P, Dallegri F. Monoclonal Lym-1 antibodydependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 1996;87:5171-8.
21. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
22. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111:5486-95.
23. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012;119:3698-704.
24. Furtado M, Dyer MJS, Johnson R, Berrow M, Rule S. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma-A phase II trial. Br J Haematol 2014;165:575-8.
25. Hunstig F, Hammersen J, Kunert C, Petersen I, Merz H, Glaser A, et al. Complete remission after treatment with single-Agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma. J Clin Oncol 2013;31:e312-e5.
26. Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol 2012; 157:438-45.
27. MatasarMJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, et al. A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT). ASH Annual Meeting Abstracts 2011;118:957-.
28. van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, et al. Ofatumumab Versus Rituximab Salvage Chemoim-munotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928). ASH Annual Meeting Abstracts 2014; 124:630.
29. Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, Matteucci P, et al. Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study. ASH Annual Meeting Abstracts 2011;118:1647.